



Genmab appoints Dr. Katja Nielsen as General Manager for Germany

Local Media Release - Germany

Copenhagen, Denmark – August 1, 2025

- **Dr. Nielsen joins Genmab at a pivotal time as the company prepares to bring its antibody-based innovative medicines to patients with an urgent medical need**
- **With 20 years of leadership experience in the pharmaceutical industry, Dr. Nielsen brings deep expertise in oncology, product launches, market access, and building high-performing teams**
- **Headquartered in Copenhagen, Genmab is an international biotech specializing in antibody-based medicines and expanding its presence in Europe**

Genmab A/S (Nasdaq: GMAB) today announced the appointment of Dr. Katja Nielsen as the General Manager for Germany as the company strengthens its commercialization capabilities in Europe and prepares to bring its innovative antibody-based medicines to more patients.

Founded in 1999 in Copenhagen, Genmab is an international biotech company that specializes in antibody-based science. The company is now expanding its commercial presence in Europe, beginning with operations in Germany.

As General Manager, Dr. Nielsen will lead Genmab's business operations in Germany, focusing on building the local footprint, driving growth and preparing for future product launches. Dr. Nielsen will join Genmab on August 1.

"Welcoming Katja to our team reflects our strategic ambition to bring our medicines to more patients around the world. She brings deep expertise in oncology, commercialization, and organizational growth to Genmab – vital capabilities as we expand our presence in one of the largest healthcare markets in Europe," said Brad Bailey, Executive Vice President and Chief Commercial Officer.

Dr. Nielsen brings over 20 years of leadership experience in the pharmaceutical industry with a strong focus on oncology, product launches, market access, and organizational leadership. She has extensive experience in leadership roles, including at Gilead, Daiichi-Sankyo, and Eli Lilly.

"I am proud to be joining Genmab, a company known for its innovative antibody science and clear purpose to improve the lives of people with cancer. We have an important opportunity to address critical needs and help bring innovative treatment options to patients in Germany," said Dr. Nielsen. "Germany is a dynamic market with unique opportunities and challenges, but as a passionate mountaineer myself, I'm used to adapting to individual challenges and discovering new ones. I look forward to helping Genmab build and scale a leading presence in Europe."

About Genmab

Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on [LinkedIn](#) and [X](#).

Contact:

Caitlin Craparo, Senior Director, Commercialization Communications
T: +1 609 255 7397; E: cacr@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Media Release contains forward-looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.